image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.5
3.11 %
$ 10 M
Market Cap
-0.78
P/E
1. INTRINSIC VALUE

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.[ Read More ]

The intrinsic value of one PETV stock under the base case scenario is HIDDEN Compared to the current market price of 0.5 USD, PetVivo Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PETV

image
FINANCIALS
969 K REVENUE
5.62%
-10.6 M OPERATING INCOME
-21.62%
-11 M NET INCOME
-25.67%
-7.42 M OPERATING CASH FLOW
-9.20%
-309 K INVESTING CASH FLOW
27.09%
7.34 M FINANCING CASH FLOW
362.59%
201 K REVENUE
62.20%
-2.17 M OPERATING INCOME
-6.29%
-2.18 M NET INCOME
-6.27%
-1.6 M OPERATING CASH FLOW
-4.56%
-3.42 K INVESTING CASH FLOW
77.47%
1.72 M FINANCING CASH FLOW
16.79%
Balance Sheet Decomposition PetVivo Holdings, Inc.
image
Current Assets 1.04 M
Cash & Short-Term Investments 87.4 K
Receivables 18.7 K
Other Current Assets 936 K
Non-Current Assets 2.07 M
Long-Term Investments 0
PP&E 2.02 M
Other Non-Current Assets 57.6 K
Current Liabilities 1.41 M
Accounts Payable 821 K
Short-Term Debt 348 K
Other Current Liabilities 243 K
Non-Current Liabilities 1.02 M
Long-Term Debt 1.02 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall PetVivo Holdings, Inc.
image
Revenue 969 K
Cost Of Revenue 229 K
Gross Profit 740 K
Operating Expenses 11.4 M
Operating Income -10.6 M
Other Expenses 334 K
Net Income -11 M
RATIOS
76.34% GROSS MARGIN
76.34%
-1096.45% OPERATING MARGIN
-1096.45%
-1130.92% NET MARGIN
-1130.92%
-1597.09% ROE
-1597.09%
-351.67% ROA
-351.67%
-574.99% ROIC
-574.99%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis PetVivo Holdings, Inc.
image
Net Income -11 M
Depreciation & Amortization 127 K
Capital Expenditures -309 K
Stock-Based Compensation 2.63 M
Change in Working Capital 172 K
Others 648 K
Free Cash Flow -7.73 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets PetVivo Holdings, Inc.
image
PETV has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership PetVivo Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
90 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7 months ago
Apr 15, 2024
Bought 90 K USD
Lai John
CEO and President
+ 150000
0.6 USD
1 year ago
Aug 21, 2023
Bought 9.91 K USD
Martin James Rudolph
Director
+ 4482
2.21 USD
1 year ago
Aug 21, 2023
Bought 654 USD
Martin James Rudolph
Director
+ 300
2.18 USD
1 year ago
Aug 21, 2023
Bought 480 USD
Martin James Rudolph
Director
+ 218
2.2 USD
1 year ago
Aug 21, 2023
Bought 4.24 K USD
Martin James Rudolph
Director
+ 1850
2.29 USD
1 year ago
Aug 21, 2023
Bought 17.2 K USD
Martin James Rudolph
Director
+ 7300
2.35 USD
1 year ago
Aug 21, 2023
Bought 1.93 K USD
Martin James Rudolph
Director
+ 850
2.27 USD
1 year ago
Aug 21, 2023
Bought 464 USD
Martin James Rudolph
Director
+ 200
2.32 USD
1 year ago
Aug 21, 2023
Bought 51.6 USD
Martin James Rudolph
Director
+ 24
2.15 USD
1 year ago
Aug 21, 2023
Bought 6.06 K USD
Martin James Rudolph
Director
+ 2600
2.33 USD
1 year ago
Aug 21, 2023
Bought 2.24 K USD
Martin James Rudolph
Director
+ 1000
2.24 USD
1 year ago
Aug 21, 2023
Bought 4.79 K USD
Martin James Rudolph
Director
+ 2100
2.28 USD
1 year ago
Aug 21, 2023
Bought 3.04 K USD
Martin James Rudolph
Director
+ 1300
2.34 USD
1 year ago
Mar 15, 2023
Bought 1.06 K USD
Costantino Robert J
Director
+ 350
3.035 USD
1 year ago
Mar 15, 2023
Bought 3.03 K USD
Costantino Robert J
Director
+ 1000
3.03 USD
1 year ago
Mar 15, 2023
Bought 6.04 K USD
Costantino Robert J
Director
+ 2000
3.02 USD
1 year ago
Mar 13, 2023
Bought 6.2 K USD
Jasper Joseph William
Director
+ 2000
3.1 USD
1 year ago
Mar 01, 2023
Bought 1.47 K USD
Jasper Joseph William
Director
+ 500
2.94 USD
1 year ago
Feb 28, 2023
Bought 1.56 K USD
Jasper Joseph William
Director
+ 501
3.12 USD
1 year ago
Feb 27, 2023
Bought 2.98 K USD
Jasper Joseph William
Director
+ 1000
2.98 USD
1 year ago
Feb 27, 2023
Bought 1.17 K USD
Jasper Joseph William
Director
+ 399
2.93 USD
1 year ago
Feb 24, 2023
Bought 1.78 K USD
Jasper Joseph William
Director
+ 600
2.96 USD
1 year ago
Feb 24, 2023
Bought 5.96 K USD
Jasper Joseph William
Director
+ 2000
2.98 USD
1 year ago
Feb 21, 2023
Bought 2.09 K USD
Martin James Rudolph
Director
+ 700
2.98 USD
1 year ago
Feb 21, 2023
Bought 299 USD
Martin James Rudolph
Director
+ 100
2.99 USD
1 year ago
Feb 21, 2023
Bought 7.5 K USD
Martin James Rudolph
Director
+ 2500
3 USD
1 year ago
Feb 16, 2023
Bought 308 USD
Martin James Rudolph
Director
+ 103
2.99 USD
1 year ago
Feb 15, 2023
Bought 1.18 K USD
Martin James Rudolph
Director
+ 400
2.95 USD
1 year ago
Feb 15, 2023
Bought 20.9 K USD
Martin James Rudolph
Director
+ 7900
2.64 USD
1 year ago
Feb 15, 2023
Bought 255 USD
Martin James Rudolph
Director
+ 100
2.55 USD
1 year ago
Feb 14, 2023
Bought 253 USD
Martin James Rudolph
Director
+ 99
2.56 USD
1 year ago
Feb 14, 2023
Bought 813 USD
Martin James Rudolph
Director
+ 300
2.71 USD
1 year ago
Feb 14, 2023
Bought 10.3 K USD
Martin James Rudolph
Director
+ 4000
2.57 USD
1 year ago
Feb 14, 2023
Bought 8.89 K USD
Martin James Rudolph
Director
+ 3500
2.54 USD
1 year ago
Nov 22, 2022
Bought 2.5 K USD
Lai John
CEO and President
+ 1000
2.5 USD
1 year ago
Nov 21, 2022
Bought 2.28 K USD
Rudelius Robert James
Director
+ 860
2.65 USD
1 year ago
Nov 21, 2022
Bought 2.55 K USD
Lai John
CEO and President
+ 1000
2.55 USD
2 years ago
Nov 18, 2022
Bought 1.04 K USD
Rudelius Robert James
Director
+ 400
2.6 USD
2 years ago
Nov 18, 2022
Bought 3.16 K USD
Rudelius Robert James
Director
+ 1240
2.55 USD
2 years ago
Nov 18, 2022
Bought 2.11 K USD
Lai John
CEO and President
+ 807
2.61 USD
2 years ago
Nov 18, 2022
Bought 779 USD
Lai John
CEO and President
+ 303
2.57 USD
2 years ago
Nov 17, 2022
Bought 2.6 K USD
Lai John
CEO and President
+ 1066
2.4399 USD
2 years ago
Nov 17, 2022
Bought 1.98 K USD
Lai John
CEO and President
+ 790
2.51 USD
2 years ago
Nov 16, 2022
Bought 86.4 USD
Lai John
CEO and President
+ 34
2.54 USD
2 years ago
Nov 16, 2022
Bought 2.44 K USD
Lai John
CEO and President
+ 1000
2.4399 USD
2 years ago
Nov 16, 2022
Bought 2.44 K USD
Lai John
CEO and President
+ 1000
2.44 USD
2 years ago
Nov 15, 2022
Bought 2.38 K USD
Lai John
CEO and President
+ 1006
2.37 USD
2 years ago
Nov 15, 2022
Bought 4.69 K USD
Lai John
CEO and President
+ 1994
2.35 USD
2 years ago
Aug 16, 2022
Bought 583 USD
Costantino Robert J
director:
+ 234
2.49 USD
2 years ago
Aug 16, 2022
Bought 1.43 K USD
Martin James Rudolph
director:
+ 578
2.47 USD
2 years ago
Aug 16, 2022
Bought 51.7 USD
Martin James Rudolph
Director
+ 22
2.35 USD
2 years ago
Aug 16, 2022
Bought 6.12 K USD
Martin James Rudolph
Director
+ 2500
2.45 USD
2 years ago
Aug 16, 2022
Bought 1.42 K USD
Martin James Rudolph
Director
+ 600
2.36 USD
2 years ago
Aug 16, 2022
Bought 708 USD
Martin James Rudolph
Director
+ 300
2.36 USD
2 years ago
Jul 01, 2022
Bought 1.35 K USD
Lai John
CEO
+ 779
1.734 USD
2 years ago
Jul 01, 2022
Bought 4.44 K USD
Lai John
CEO
+ 2544
1.745 USD
2 years ago
Jul 01, 2022
Bought 12 K USD
Lai John
CEO
+ 6677
1.79 USD
2 years ago
Feb 28, 2022
Bought 11.4 K USD
Martin James Rudolph
Director
+ 7500
1.5191 USD
3 years ago
Aug 13, 2021
Bought 18 K USD
Johnson Scott Mitchell
Director
+ 4000
4.5 USD
3 years ago
May 04, 2021
Sell 885 USD
Johnson Scott Mitchell
Director
- 100
8.85 USD
3 years ago
May 04, 2021
Sell 783 USD
Johnson Scott Mitchell
Director
- 90
8.7 USD
3 years ago
May 05, 2021
Sell 16.4 K USD
Johnson Scott Mitchell
Director
- 2115
7.75 USD
3 years ago
May 10, 2021
Sell 2.3 K USD
Johnson Scott Mitchell
Director
- 271
8.5 USD
3 years ago
May 10, 2021
Sell 8.12 K USD
Johnson Scott Mitchell
Director
- 950
8.55 USD
3 years ago
Aug 13, 2021
Bought 22.5 K USD
Johnson Scott Mitchell
Director
+ 4000
5.625 USD
3 years ago
Oct 05, 2021
Bought 1.47 K USD
Martin James Rudolph
Director
+ 600
2.4499 USD
3 years ago
Oct 05, 2021
Bought 1.23 K USD
Martin James Rudolph
Director
+ 500
2.4645 USD
3 years ago
Oct 05, 2021
Bought 1.24 K USD
Martin James Rudolph
Director
+ 500
2.47 USD
3 years ago
Sep 14, 2021
Bought 3.55 K USD
Martin James Rudolph
Director
+ 1200
2.96 USD
3 years ago
Sep 13, 2021
Bought 3.24 K USD
Martin James Rudolph
Director
+ 1000
3.24 USD
3 years ago
Sep 13, 2021
Bought 1.58 K USD
Martin James Rudolph
Director
+ 500
3.17 USD
3 years ago
Sep 13, 2021
Bought 4.8 K USD
Martin James Rudolph
Director
+ 1500
3.2 USD
3 years ago
Sep 13, 2021
Bought 6.5 K USD
Martin James Rudolph
Director
+ 2000
3.25 USD
3 years ago
Sep 13, 2021
Bought 6.54 K USD
Martin James Rudolph
Director
+ 2000
3.2699 USD
3 years ago
Sep 02, 2021
Bought 8.48 K USD
Folkes Robert J.
Chief Financial Officer
+ 2147
3.95 USD
3 years ago
Sep 02, 2021
Bought 7.26 K USD
Folkes Robert J.
Chief Financial Officer
+ 1843
3.94 USD
3 years ago
Sep 02, 2021
Bought 393 USD
Folkes Robert J.
Chief Financial Officer
+ 100
3.93 USD
3 years ago
Sep 02, 2021
Bought 39 USD
Folkes Robert J.
Chief Financial Officer
+ 10
3.9 USD
3 years ago
Sep 02, 2021
Bought 22.9 K USD
Folkes Robert J.
Chief Financial Officer
+ 5895
3.89 USD
3 years ago
Sep 02, 2021
Bought 18.7 USD
Folkes Robert J.
Chief Financial Officer
+ 5
3.74 USD
3 years ago
Aug 25, 2021
Bought 1.83 K USD
Martin James Rudolph
Director
+ 700
2.6092 USD
3 years ago
Aug 25, 2021
Bought 3.51 K USD
Martin James Rudolph
Director
+ 1300
2.7 USD
3 years ago
Aug 11, 2021
Bought 11.2 K USD
Martin James Rudolph
Director
+ 2500
4.49 USD
3 years ago
Aug 11, 2021
Bought 17.4 K USD
Martin James Rudolph
Director
+ 5000
3.4848 USD
3 years ago
Jun 02, 2021
Bought 5.6 K USD
Deming David Don
Director
+ 800
7 USD
3 years ago
May 28, 2021
Bought 21 K USD
Folkes Robert J.
CFO
+ 3000
7 USD
3 years ago
Apr 24, 2021
Bought 21 K USD
Martin James Joseph
Director
+ 3000
7 USD
4 years ago
May 14, 2020
Bought 5.08 K USD
CASH GREGORY D
Director
+ 20002
0.2538 USD
4 years ago
May 14, 2020
Bought 10.2 K USD
Martin James Rudolph
Director
+ 40004
0.2538 USD
4 years ago
Jul 16, 2020
Bought 4 K USD
Johnson Scott Mitchell
Director
+ 5000
0.8 USD
4 years ago
Jul 13, 2020
Bought 2.7 K USD
Martin James Rudolph
Director
+ 3000
0.9 USD
4 years ago
Jul 09, 2020
Bought 712 USD
Johnson Scott Mitchell
Director
+ 925
0.77 USD
4 years ago
Jul 08, 2020
Bought 3.38 K USD
Johnson Scott Mitchell
Director
+ 4070
0.83 USD
4 years ago
Jul 09, 2020
Bought 813 USD
Martin James Rudolph
Director
+ 1000
0.8134 USD
4 years ago
Jul 08, 2020
Bought 2.23 K USD
Martin James Rudolph
Director
+ 2400
0.93 USD
4 years ago
Jul 06, 2020
Bought 2.9 K USD
Martin James Rudolph
Director
+ 4684
0.62 USD
4 years ago
Jul 06, 2020
Bought 1.72 K USD
Martin James Rudolph
Director
+ 3300
0.52 USD
4 years ago
Jul 06, 2020
Bought 3 K USD
Martin James Rudolph
Director
+ 6000
0.5 USD
4 years ago
Jul 02, 2020
Bought 1.84 K USD
Martin James Rudolph
Director
+ 4000
0.46 USD
4 years ago
Jul 02, 2020
Bought 490 USD
Martin James Rudolph
Director
+ 1090
0.45 USD
4 years ago
Jul 02, 2020
Bought 2.29 K USD
Martin James Rudolph
Director
+ 5210
0.44 USD
4 years ago
Jun 30, 2020
Bought 1.22 K USD
Martin James Rudolph
Director
+ 2766
0.44 USD
4 years ago
Jun 30, 2020
Bought 1.23 K USD
Martin James Rudolph
Director
+ 3067
0.4 USD
4 years ago
Jun 30, 2020
Bought 1.05 K USD
Martin James Rudolph
Director
+ 2667
0.395 USD
4 years ago
Jun 30, 2020
Bought 982 USD
Martin James Rudolph
Director
+ 2500
0.393 USD
4 years ago
May 14, 2020
Bought 10 K USD
Martin James Rudolph
Director
+ 39401
0.2538 USD
4 years ago
Jun 08, 2020
Bought 2.96 K USD
Martin James Rudolph
Director
+ 8000
0.37 USD
4 years ago
Jun 05, 2020
Bought 2.13 K USD
Martin James Rudolph
Director
+ 5750
0.37 USD
4 years ago
Jun 01, 2020
Bought 1 K USD
Martin James Rudolph
Director
+ 3030
0.33 USD
4 years ago
May 29, 2020
Bought 675 USD
Martin James Rudolph
Director
+ 2500
0.27 USD
4 years ago
May 29, 2020
Bought 2.1 K USD
Martin James Rudolph
Director
+ 7500
0.28 USD
4 years ago
Nov 29, 2019
Bought 1 K USD
Martin James Rudolph
Director
+ 2500
0.4 USD
5 years ago
Nov 14, 2019
Bought 4 K USD
Martin James Rudolph
Director
+ 10000
0.4 USD
5 years ago
Nov 04, 2019
Bought 1.02 K USD
Martin James Rudolph
Director
+ 2500
0.41 USD
5 years ago
Oct 03, 2019
Bought 988 USD
Martin James Rudolph
Director
+ 2500
0.395 USD
5 years ago
Sep 03, 2019
Bought 1.44 K USD
Martin James Rudolph
Director
+ 4250
0.34 USD
5 years ago
Sep 03, 2019
Bought 1.44 K USD
Martin James Rudolph
Director
+ 4250
0.34 USD
5 years ago
Sep 03, 2019
Bought 1.5 K USD
Martin James Rudolph
Director
+ 5000
0.3 USD
6 years ago
Mar 01, 2018
Bought 1.81 K USD
Deming David Don
Director
+ 1000
1.81 USD
10 years ago
Aug 14, 2014
Bought 16 K USD
Dolan John F.
CFO
+ 2666667
0.006 USD
10 years ago
Aug 14, 2014
Bought 24 K USD
Lai John
President
+ 4000000
0.006 USD
10 years ago
Apr 01, 2014
Bought 48 K USD
Lai John
CEO
+ 3200000
0.015 USD
7. News
PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript PetVivo Holdings, Inc. (OTCPK:PETV) Q2 2025 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer and General Counsel John Lai - Chief Executive Officer Garry Lowenthal - Chief Financial Officer Conference Call Participants John Dolan Good afternoon, everyone. Thank you for joining us today to discuss PetVivo's Results for its Fiscal Second Quarter ended September 30, 2024. seekingalpha.com - 2 days ago
PetVivo Reports Fiscal Q2 2025 Results MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal second quarter ended September 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. globenewswire.com - 2 days ago
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2024 MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, November 14, 2024 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. globenewswire.com - 5 days ago
PetVivo Engages Another Top Sales Manager, Cindy Gill, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. globenewswire.com - 3 weeks ago
Accel Media International Celebrates 5-Year Anniversary With Expanded Billboard Access, Dynamic Taxi Tops, and Multi-Channel Media Solutions Through New to The Street AMI continues to expand its media portfolio by adding programmable Taxi Tops and multiple billboards in Las Vegas, ensuring unmatched exposure for its clients. NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Accel Media International (AMI) proudly celebrates its 5-year anniversary, marking a period of remarkable growth and innovation. accesswire.com - 1 month ago
PetVivo Meets Growing Demand for Spryng™ with Appointment of Veterinary Surgeon, Kirsty Husby, as Senior Technical Services Veterinarian Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals globenewswire.com - 2 months ago
Delisting of Securities of Liberty Resources Acquisition Corp.; Achari Ventures Holdings Corp. I; PetVivo Holdings, Inc.; Galera Therapeutics, Inc.; Clean Energy Special Situations Corp.; Capitalworks Emerging Markets Acquisition Corp.; AERWINS Technologies Inc.; Biolase, Inc.; Global Gas Corporation; Corner Growth Acquisition Corp.; Lucy Scientific Discovery Inc.; Chicken Soup for the Soul Entertainment, Inc.; Ideanomics, Inc.; NexImmune, Inc.; Shapeways Holdings, Inc.; QIWI plc; ASLAN Pharmaceuticals Limited; Conn's, Inc.; 2U, Inc.; International Media Acquisition Corp.; Presto Automation, Inc.; and VBI Vaccines, Inc.; from The Nasdaq Stock Market ASLAN Pharmaceuticals Limited; Conn's, Inc.; 2U, Inc.; International Media Acquisition Corp.; Presto Automation, Inc.; and VBI Vaccines, Inc.; from The Nasdaq Stock Market globenewswire.com - 2 months ago
Scot Cave Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager MINNEAPOLIS, MN, US, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Scot Cave has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover the Northwest Region of the United States. globenewswire.com - 2 months ago
Anthony Germinaro Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager MINNEAPOLIS, MN, US, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Anthony Germinaro has accepted a position with the Company as its new Field Veterinary Business Development Manager for the for the Southwest Region of the United States. globenewswire.com - 2 months ago
PetVivo Holdings, Inc. (PETV) Q1 2025 Earnings Call Transcript PetVivo Holdings, Inc. (OTCPK:PETV) Q1 2025 Earnings Call August 14, 2024 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer and General Counsel John Lai - Chief Executive Officer Garry Lowenthal - Chief Financial Officer John Dolan Good afternoon, everyone. Thank you for joining us today to discuss PetVivo's Results for its Fiscal First Quarter Ended June 30, 2024. seekingalpha.com - 3 months ago
PetVivo Reports Reports Fiscal Q1 2025 Results Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025 MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal first quarter ended June 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. globenewswire.com - 3 months ago
Eric Samples Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager MINNEAPOLIS, MN, US, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Eric Samples has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover Ohio, Pennsylvania, and the Baltimore/DC area of the United States. globenewswire.com - 3 months ago
8. Profile Summary

PetVivo Holdings, Inc. PETV

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 10 M
Dividend Yield 0.00%
Description PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Contact 5251 Edina Industrial Boulevard, Minneapolis, MN, 55439 https://www.petvivo.com
IPO Date Sept. 8, 2014
Employees 20
Officers Mr. Gary DeMel Executive Vice President of Business Development Ms. April Boyce Vice President of Marketing Mr. Bryan Monninger Vice President of Sales Mr. John Lai Chief Executive Officer, President & Director Mr. Randy Wenthold Chief Science Officer Mr. Garry N. Lowenthal Chief Financial Officer Mr. Randall A. Meyer Chief Operating Officer Mr. John F. Dolan General Counsel, Chief Business Development Officer & Secretary